TWI299041B - Bi-and tricyclic substituted phenyl methanones - Google Patents
Bi-and tricyclic substituted phenyl methanones Download PDFInfo
- Publication number
- TWI299041B TWI299041B TW094143890A TW94143890A TWI299041B TW I299041 B TWI299041 B TW I299041B TW 094143890 A TW094143890 A TW 094143890A TW 94143890 A TW94143890 A TW 94143890A TW I299041 B TWI299041 B TW I299041B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- alkyl
- formula
- group
- dihydro
- Prior art date
Links
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical class O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 description 31
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 10
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 229930192474 thiophene Natural products 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 3
- -1 2-isopropoxy-5-methanesulfonyl-phenyl Chemical group 0.000 description 3
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical group [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 150000002367 halogens Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 229910052707 ruthenium Inorganic materials 0.000 description 3
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- QGIGNHJWEORARI-UHFFFAOYSA-N 1-(2-methylpropoxy)-4-methylsulfonylbenzene Chemical compound CC(C)COC1=CC=C(S(C)(=O)=O)C=C1 QGIGNHJWEORARI-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04106597 | 2004-12-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200634017A TW200634017A (en) | 2006-10-01 |
| TWI299041B true TWI299041B (en) | 2008-07-21 |
Family
ID=35841863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094143890A TWI299041B (en) | 2004-12-15 | 2005-12-12 | Bi-and tricyclic substituted phenyl methanones |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7375226B2 (https=) |
| EP (1) | EP1828200B1 (https=) |
| JP (1) | JP4709849B2 (https=) |
| KR (1) | KR100883003B1 (https=) |
| CN (1) | CN100586951C (https=) |
| AR (1) | AR052156A1 (https=) |
| AT (1) | ATE457989T1 (https=) |
| AU (1) | AU2005315914B2 (https=) |
| BR (1) | BRPI0519054A2 (https=) |
| CA (1) | CA2590316A1 (https=) |
| DE (1) | DE602005019465D1 (https=) |
| ES (1) | ES2338139T3 (https=) |
| IL (1) | IL183592A0 (https=) |
| MX (1) | MX2007006896A (https=) |
| NO (1) | NO20072833L (https=) |
| NZ (1) | NZ555476A (https=) |
| RU (1) | RU2007121768A (https=) |
| TW (1) | TWI299041B (https=) |
| WO (1) | WO2006063709A1 (https=) |
| ZA (1) | ZA200705044B (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7485637B2 (en) * | 2005-01-04 | 2009-02-03 | Hoffmann-La Roche Inc. | Benzoyl-tetrahydropiperidine derivatives |
| RU2338537C2 (ru) * | 2006-01-25 | 2008-11-20 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| KR102107954B1 (ko) | 2007-03-12 | 2020-05-07 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| EP2527328A1 (en) | 2008-04-01 | 2012-11-28 | Abbott GmbH & Co. KG | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy |
| EP2393878B1 (de) | 2009-02-06 | 2012-12-12 | Styrolution GmbH | Thermoplastische formmassen auf basis von styrolcopolymeren und polyamiden mit verbesserter witterungsbeständigkeit |
| AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
| TW201038569A (en) * | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
| US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| CA2806103A1 (en) * | 2010-08-31 | 2012-03-08 | Vanderbilt University | Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mglur5 receptors |
| US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8853196B2 (en) | 2011-08-05 | 2014-10-07 | AbbVie Deutschland GmbH & Co. KG | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| CN104011028A (zh) | 2011-11-18 | 2014-08-27 | 艾伯维德国有限责任两合公司 | N-取代的氨基苯并环庚烯、氨基四氢化萘、氨基茚满和苯烷基胺衍生物、包含所述衍生物的药物组合物及其在治疗中的用途 |
| AU2012357169B2 (en) * | 2011-12-22 | 2017-03-30 | Merck Patent Gmbh | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators |
| US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| CN104203951B (zh) * | 2012-03-16 | 2016-11-02 | 生命医药公司 | 肝x受体调节剂 |
| WO2013138568A1 (en) * | 2012-03-16 | 2013-09-19 | Vitae Pharmaceuticals, Inc. | Liver x reception modulators |
| KR20140146192A (ko) | 2012-04-14 | 2014-12-24 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9708322B2 (en) | 2013-03-15 | 2017-07-18 | Intra-Cellular Therapies, Inc. | Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity |
| US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| WO2015055770A1 (en) | 2013-10-17 | 2015-04-23 | AbbVie Deutschland GmbH & Co. KG | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| SG11201602935PA (en) | 2013-10-17 | 2016-05-30 | Abbvie Deutschland | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| KR102373288B1 (ko) | 2013-12-03 | 2022-03-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| US10077267B2 (en) | 2014-04-04 | 2018-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CA2944755A1 (en) | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| PL3838274T3 (pl) | 2016-01-26 | 2024-04-02 | Intra-Cellular Therapies, Inc. | Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN |
| DK3407889T3 (da) | 2016-03-25 | 2021-08-09 | Intra Cellular Therapies Inc | Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet |
| EP3436455A4 (en) | 2016-03-28 | 2019-09-04 | Intra-Cellular Therapies, Inc. | NOVEL SALTS AND CRYSTALS |
| US11014925B2 (en) | 2016-03-28 | 2021-05-25 | Intra-Cellular Therapies, Inc. | Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| EP3525763B1 (en) | 2016-10-12 | 2025-03-05 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| EP3562484B1 (en) | 2016-12-29 | 2021-08-25 | Intra-Cellular Therapies, Inc. | Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| RU2767410C2 (ru) | 2017-03-24 | 2022-03-17 | Интра-Селлулар Терапиз, Инк. | Новые композиции и способы |
| EP3658144B1 (en) | 2017-07-26 | 2022-01-26 | Intra-Cellular Therapies, Inc. | Pyridopyrroloquinoxaline compounds, their compositions and uses in therapy |
| WO2019023062A1 (en) | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
| CN112040940A (zh) | 2018-03-23 | 2020-12-04 | 细胞内治疗公司 | 有机化合物 |
| AU2019280850C1 (en) | 2018-06-06 | 2025-02-13 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
| EP3801527B1 (en) | 2018-06-08 | 2025-02-19 | Intra-Cellular Therapies, Inc. | Fused gamma-carbolines for acute treatment of anxiety or depression |
| CA3240552A1 (en) | 2018-06-11 | 2019-12-19 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| US12144808B2 (en) | 2018-08-29 | 2024-11-19 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| WO2020047408A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| BR112021003655A2 (pt) | 2018-08-31 | 2021-05-18 | Intra-Cellular Therapies, Inc. | métodos novos |
| JP7520013B2 (ja) | 2018-12-17 | 2024-07-22 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 置換複素環縮合γ－カルボリンの合成 |
| IL315005B2 (en) | 2018-12-17 | 2026-04-01 | Intra Cellular Therapies Inc | Synthesis of condensed gamma-carbolines and converted heterocycles |
| WO2021007245A1 (en) | 2019-07-07 | 2021-01-14 | Intra-Cellular Therapies, Inc. | Novel methods |
| EP4072554A4 (en) | 2019-12-11 | 2023-12-20 | Intra-Cellular Therapies, Inc. | ORGANIC CONNECTION |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2423847A1 (de) * | 1973-05-28 | 1975-01-02 | Ciba Geigy Ag | Neue sulfamoylbenzoesaeureamide |
| DE2611705A1 (de) * | 1976-03-18 | 1977-09-22 | Josef Dipl Chem Dr Rer N Klosa | N-5-(nitrofurfuryliden-)-1-amino- hydantoin enthaltende kristalloesungsmittel |
| IT1176613B (it) | 1984-08-14 | 1987-08-18 | Ravizza Spa | Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione |
| RU2124511C1 (ru) | 1993-05-14 | 1999-01-10 | Фармасьютикал Ко., Лтд | Производные пиперазина |
| JPH08325234A (ja) * | 1995-05-30 | 1996-12-10 | Yamanouchi Pharmaceut Co Ltd | 安息香酸誘導体又はその塩 |
| US6001854A (en) * | 1996-05-31 | 1999-12-14 | Allelix Neuroscience Inc. | Pharmaceutical for treating of neurological and neuropsychiatric disorders |
| PL343435A1 (en) * | 1998-03-06 | 2001-08-13 | Janssen Pharmaceutica Nv | Glycine transport inhibitors |
| EP1058684A1 (en) * | 1998-03-06 | 2000-12-13 | Janssen Pharmaceutica N.V. | Glycine transport inhibitors |
| EP1296950A2 (en) * | 2000-04-20 | 2003-04-02 | NPS Allelix Corp. | Aminopiperidines for use as glyt-1 inhibitors |
| GB0021419D0 (en) | 2000-08-31 | 2000-10-18 | Oxford Glycosciences Uk Ltd | Compounds |
| ATE449090T1 (de) | 2001-07-02 | 2009-12-15 | High Point Pharmaceuticals Llc | Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren |
| WO2003035602A1 (en) | 2001-10-25 | 2003-05-01 | Sankyo Company, Limited | Lipid modulators |
| TWI329111B (en) * | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| WO2004037800A1 (en) | 2002-10-22 | 2004-05-06 | Glaxo Group Limited | Aryloxyalkylamine derivates as h3 receptor ligands |
| RS53252B (sr) * | 2003-08-11 | 2014-08-29 | F.Hoffmann-La Roche Ag. | Piperazin sa or-supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1 |
| CN1874777B (zh) * | 2003-09-09 | 2012-07-04 | 弗·哈夫曼-拉罗切有限公司 | 作为甘氨酸摄取抑制剂用于治疗精神病的1-(2-氨基-苯甲酰基)-哌嗪衍生物 |
| WO2005023261A1 (en) * | 2003-09-09 | 2005-03-17 | F. Hoffmann-La Roche Ag | 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses |
-
2005
- 2005-12-05 AT AT05823127T patent/ATE457989T1/de active
- 2005-12-05 JP JP2007545891A patent/JP4709849B2/ja not_active Expired - Fee Related
- 2005-12-05 AU AU2005315914A patent/AU2005315914B2/en not_active Ceased
- 2005-12-05 CN CN200580042730A patent/CN100586951C/zh not_active Expired - Fee Related
- 2005-12-05 ES ES05823127T patent/ES2338139T3/es not_active Expired - Lifetime
- 2005-12-05 MX MX2007006896A patent/MX2007006896A/es active IP Right Grant
- 2005-12-05 DE DE602005019465T patent/DE602005019465D1/de not_active Expired - Lifetime
- 2005-12-05 NZ NZ555476A patent/NZ555476A/en not_active IP Right Cessation
- 2005-12-05 RU RU2007121768/04A patent/RU2007121768A/ru not_active Application Discontinuation
- 2005-12-05 WO PCT/EP2005/012994 patent/WO2006063709A1/en not_active Ceased
- 2005-12-05 KR KR1020077013440A patent/KR100883003B1/ko not_active Expired - Fee Related
- 2005-12-05 CA CA002590316A patent/CA2590316A1/en not_active Abandoned
- 2005-12-05 BR BRPI0519054-1A patent/BRPI0519054A2/pt not_active IP Right Cessation
- 2005-12-05 EP EP05823127A patent/EP1828200B1/en not_active Expired - Lifetime
- 2005-12-08 US US11/297,597 patent/US7375226B2/en not_active Expired - Fee Related
- 2005-12-12 TW TW094143890A patent/TWI299041B/zh not_active IP Right Cessation
- 2005-12-13 AR ARP050105207A patent/AR052156A1/es not_active Application Discontinuation
-
2007
- 2007-05-31 IL IL183592A patent/IL183592A0/en unknown
- 2007-06-04 NO NO20072833A patent/NO20072833L/no not_active Application Discontinuation
- 2007-06-07 ZA ZA200705044A patent/ZA200705044B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE457989T1 (de) | 2010-03-15 |
| NZ555476A (en) | 2009-09-25 |
| AU2005315914B2 (en) | 2011-03-03 |
| AR052156A1 (es) | 2007-03-07 |
| IL183592A0 (en) | 2007-09-20 |
| CN101076532A (zh) | 2007-11-21 |
| KR100883003B1 (ko) | 2009-02-12 |
| DE602005019465D1 (de) | 2010-04-01 |
| ZA200705044B (en) | 2008-09-25 |
| AU2005315914A1 (en) | 2006-06-22 |
| EP1828200B1 (en) | 2010-02-17 |
| ES2338139T3 (es) | 2010-05-04 |
| WO2006063709A1 (en) | 2006-06-22 |
| KR20070086196A (ko) | 2007-08-27 |
| US7375226B2 (en) | 2008-05-20 |
| BRPI0519054A2 (pt) | 2008-12-23 |
| JP4709849B2 (ja) | 2011-06-29 |
| NO20072833L (no) | 2007-07-17 |
| JP2008523126A (ja) | 2008-07-03 |
| US20060128713A1 (en) | 2006-06-15 |
| CN100586951C (zh) | 2010-02-03 |
| RU2007121768A (ru) | 2009-01-27 |
| EP1828200A1 (en) | 2007-09-05 |
| CA2590316A1 (en) | 2006-06-22 |
| TW200634017A (en) | 2006-10-01 |
| MX2007006896A (es) | 2007-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI299041B (en) | Bi-and tricyclic substituted phenyl methanones | |
| ES2948192T3 (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina D1 | |
| TW201211037A (en) | 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE) | |
| JP2006517966A (ja) | ５−ヒドロキシトリプタミン−６リガンドとしてのヘテロサイクリル−３−スルホニルアザインドールまたは−アザインダゾール誘導体 | |
| CN103214414A (zh) | 旋光性的二胺衍生物及其制造方法 | |
| CA2770724A1 (en) | 5-ht inhibiting indole compounds | |
| FR2786770A1 (fr) | Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique | |
| TW201116532A (en) | Metabotropic glutamate receptor modulators | |
| CN104837839A (zh) | 作为多巴胺d1配体的杂芳族化合物 | |
| TW200813062A (en) | Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions | |
| JP2000502662A (ja) | ヘテロアリールカルボキサミド誘導体 | |
| US10023534B2 (en) | Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK | |
| JP2001199956A (ja) | 光学活性なインドリン誘導体の製造方法およびその製造中間体 | |
| TW201038539A (en) | Therapeutic applications of quinazolinedione derivatives | |
| TW200911802A (en) | 7-alkynyl-1,8-naphthyridone derivatives, preparation thereof and therapeutic use thereof | |
| CN108884093B (zh) | 一种多巴胺d3配体化合物 | |
| JP4939719B2 (ja) | １，４−ジアザビシクロ［３．２．２］ノナン−フェニルイソオキサゾール誘導体、その製法と治療用途 | |
| JP2006516653A (ja) | キナーゼ阻害剤ピロロトリアジンの製造方法 | |
| HUP0302925A2 (hu) | Gyulladásgátló szerekként alkalmazható amino-szubsztituált tetraciklusos vegyületek és ezeket tartalmazó gyógyszerkészítmények | |
| JPWO2002026745A1 (ja) | チエノピリミジン化合物とその塩並びに製造方法 | |
| CN112424198A (zh) | 噻二嗪衍生物 | |
| CA2584757A1 (en) | Halogen substituted benzodiazepine derivatives | |
| TW200836726A (en) | Pyrrolopyridine-2-carboxamide derivatives, preparation thereof and therapeutic use thereof | |
| AU2017388054B2 (en) | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | |
| TW200305413A (en) | Derivatives of 5- (pyridin-3-yl)-1-azabicyclo [3. 2. 1] octane, their preparation and their therapeutic application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |